Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSTAR: Idasanutlin and Selinexor for Rhabdoid Tumors
NCT05952687Phase 1Withdrawn
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of idasanutlin and selinexor in Atypical teratoid rhabdoid tumor (ATRT) and malignant rhabdoid tumor (MRT) (4 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose at 1 month, Recommended Phase 2 Dose at 1 month and 2 more. Planned start Mar 2024; status: withdrawn.
02
Drugs
idasanutlinselinexor
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)malignant rhabdoid tumor (MRT)
Beyond the preview
Go deeper on NCT05952687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952687.